Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines.

Negative-strand RNA viruses (NSVs) are a group of viruses that possess a genome made of RNA, which is complementary to the mRNA needed for protein ... on the respiratory syncytial virus (RSV ...

COVID-19 and flu activity is increasing in most parts of the country and RSV activity remains very high, especially in young children. Respiratory illness activity in Florida is very high ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

But there's a fourth "bug" the public should be aware of: respiratory syncytial virus. RSV causes cold-like symptoms and affects the breathing passages and lungs. Wastewater levels of RSV are ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

For those 60 and older or for people who are pregnant, you may want to get the RSV vaccine. Your immune system may not work as well if you’re sleep-deprived, stressed out or dehydrated.